Out With the Old and in With AI
Artificial Intelligence and other innovative technologies have the potential to disrupt every stage of the clinical trial process as we currently know it. It is high time we put these technologies to use.
Chris Tackaberry |
Despite being vital to new drug development, the clinical trial process is broken. Patient recruitment and retention provide such significant challenges that their impact is felt industry wide. More than three-quarters of all clinical trials experience delays and with the daily bill for this somewhere between $600,000 and $8 million, the desire to find a more efficient method sits right at the top of the agenda. In addition to the astronomical costs, the stark reality is that these delays often slow down the entry of new medicines into the market, preventing patients from accessing new and innovative treatments. Even when patients are willing to participate, the hurdles are still significant; not least because the whole business of clinical trials is shrouded in mystery with very few people understanding or acknowledging the role they could play by participating.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.